ProBioGen AG, a service & technology provider for complex therapeutic glycoproteins, has signed a second clinical immuno-oncology development and manufacturing agreement with Tizona Therapeutics, Inc., a privately held immunology company, to develop treatments for cancer.     Under the terms of the agreement, ProBioGen is developing a stable cell line, followed by process development and GMP clinical manufacturing for Tizona’s lead antibody drug candidate.   “Tizona Therapeut...